在早期瘤学临床试验中,从剂量发现到剂量优化
Elvina Almuradova1, Davide Izzo2, Sara Gandini3
1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Ege University Hospital, Department of Medical Oncology, Izmir, Turkey.
Cancer treatment reviews
|March 29, 2025
概括
在早期试验中优化癌症药物剂量至关重要. 现代方法使用生物标志物和患者数据来实现更安全,更有效的个性化癌症治疗,超越了传统的以安全为中心的设计.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
背景情况:
- 传统的I期瘤学试验设计,如3+3方法,优先考虑安全性,但可能导致低于最佳剂量.
- 这些方法往往不能适应新型癌症疗法的复杂药理动力学和药理动力学,包括向药物和免疫疗法.
研究的目的:
- 在I期瘤学试验中审查当前的剂量优化策略.
- 突出传统剂量升级方法的局限性,并倡导现代,以患者为中心的方法.
主要方法:
- 对有关I期瘤学试验设计的现有文献的审查.
- 讨论结合生物标志物,药理动力学/药理动力学分析和患者报告结果的创新策略.
主要成果:
- 传统方法可能会导致长时间暴露于无效或有毒剂量.
- 当代方法提高了剂量选择的精度,并支持个性化癌症护理.
结论:
- 区分剂量发现和剂量优化对于有效的早期试验至关重要.
- 将患者的观点和药理学的见解整合到试验设计中,可以加速提供量身定制的癌症疗法.
更多相关视频
相关概念视频
Clinical Trials
8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
8.5K
Drug Discovery: Overview
10.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.4K
Clinical Trials: Overview
4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Preclinical Development: Overview
4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Dose Size and Dosing Frequency: Determination Methods
804
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
804
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
394
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
394


